#1 Clinical Trials Search in Europe

Famotidine

Famotidine, commonly known as Pepcid, is a medication traditionally used to reduce stomach acid production. Recent clinical trials have been exploring its potential applications beyond its primary use, including its effects on COVID-19 patients and individuals with Parkinson’s disease. This article summarizes key findings from various clinical trials investigating famotidine’s efficacy, safety, and potential new uses in medical treatments.

Table of Contents

What is Famotidine?

Famotidine is a medication that belongs to a class of drugs called histamine-2 (H2) receptor antagonists, also known as H2 blockers. It is widely available over-the-counter and is commonly used to suppress gastric acid production[1]. Famotidine is sold under various brand names, including Pepcid, Pepcid AC, and Famotac[2][3].

Uses of Famotidine

Famotidine is primarily used to treat conditions related to excess stomach acid. These include:

  • Heartburn: Famotidine helps reduce the discomfort caused by acid reflux[4].
  • Gastroesophageal Reflux Disease (GERD): It can help manage symptoms of GERD by reducing stomach acid production.
  • Peptic Ulcers: Famotidine can aid in the healing of ulcers in the stomach and small intestine.
  • Zollinger-Ellison Syndrome: This rare condition causes excess stomach acid production, which famotidine can help control.

In addition to these established uses, researchers are exploring the potential of famotidine in treating other conditions, such as COVID-19[5] and levodopa-induced dyskinesia in Parkinson’s disease[6].

How Famotidine Works

Famotidine works by blocking histamine-2 receptors in the stomach. Histamine is a natural chemical in the body that stimulates the production of stomach acid. By blocking these receptors, famotidine reduces the amount of acid produced by the stomach[1]. This mechanism helps alleviate symptoms caused by excess stomach acid and allows damaged tissues in the digestive tract to heal.

Dosage and Administration

Famotidine is available in various forms and dosages, including:

  • Tablets (20 mg, 40 mg)[3]
  • Chewable tablets (20 mg)[4]
  • Film-coated tablets (20 mg)[4]

The dosage and frequency of administration depend on the condition being treated and can range from 20 mg once daily to 160 mg four times daily[1]. It’s important to follow your healthcare provider’s instructions or the directions on the product label.

Famotidine can be taken with or without food. Some formulations, like chewable tablets, may be taken without water, while others should be swallowed whole with a glass of water[4].

Potential Side Effects

While famotidine is generally well-tolerated, some people may experience side effects. Common side effects may include:

  • Headache
  • Dizziness
  • Constipation or diarrhea
  • Nausea
  • Fatigue

Serious side effects are rare but can occur. If you experience any unusual symptoms while taking famotidine, contact your healthcare provider immediately[7].

Ongoing Research

Researchers are currently investigating the potential of famotidine in treating various conditions beyond its traditional use for acid-related disorders. Some areas of ongoing research include:

  • COVID-19: Studies are exploring whether famotidine can help improve symptoms and outcomes in patients with COVID-19[5][8].
  • Parkinson’s Disease: Researchers are investigating if famotidine can help reduce levodopa-induced dyskinesia (involuntary movements) in patients with Parkinson’s disease[6].
  • Drug Interactions: Studies are being conducted to understand how famotidine might interact with other medications, such as afimetoran[7].

It’s important to note that while these research areas are promising, more studies are needed to confirm the effectiveness and safety of famotidine for these potential new uses.

Aspect Details
Primary Use Reduction of stomach acid production
New Potential Uses COVID-19 symptom reduction, Parkinson’s disease dyskinesia treatment
Dosage Range in Trials 20mg to 160mg per day
Administration Methods Oral tablets, chewable tablets, film-coated tablets
Key Outcome Measures Symptom resolution, hospitalization rates, adverse events
Safety Profile Generally considered safe, with ongoing monitoring in trials
Pharmacokinetic Studies Bioavailability and bioequivalence assessments

FAQ

  • What is famotidine primarily used for? Famotidine is primarily used as a histamine-2 receptor antagonist to reduce stomach acid production. It's commonly used to treat conditions like heartburn, acid reflux, and stomach ulcers.
  • Are there any potential new uses for famotidine being studied? Yes, recent clinical trials have been exploring famotidine's potential use in treating COVID-19 symptoms and reducing levodopa-induced dyskinesia in Parkinson's disease patients.
  • How is famotidine being studied in relation to COVID-19? Clinical trials are investigating whether famotidine can help reduce symptoms in non-hospitalized COVID-19 patients with mild to moderate disease. Some studies are comparing famotidine to placebo to assess its efficacy in symptom resolution and preventing hospitalization.
  • What doses of famotidine are being studied in clinical trials? Various doses are being studied, ranging from 20mg to 160mg per day. For COVID-19 treatment, some trials are using higher doses like 80mg three times daily.
  • Are there any known side effects of famotidine in these trials? While famotidine is generally considered safe, clinical trials are monitoring for potential adverse events. Common side effects may include headache, dizziness, and constipation. Serious side effects are rare but are being closely monitored in these studies.

Ongoing Clinical Trials on Famotidine

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Italy The Netherlands Portugal +1

  • Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Greece Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Norway

  • Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

    Recruiting

    1 1 1
    Investigated drugs:
    France The Netherlands Spain

  • Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Effects of Plitidepsin for Adults with Long COVID Symptoms

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Plitidepsin Treatment for Adults with Post-COVID-19 Condition

    Not recruiting

    1 1
    Investigated drugs:
    Spain

  • Study on the Safety and Effects of THOR-707 and Drug Combination in Adults with Advanced or Metastatic Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Bioavailability: The extent and rate at which a drug enters the body's circulation to produce an active effect.
  • Histamine-2 receptor antagonist: A type of medication that blocks histamine receptors in the stomach, reducing acid production.
  • Levodopa-induced dyskinesia: Involuntary movements that can occur as a side effect of long-term levodopa treatment in Parkinson's disease patients.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Area Under Curve (AUC): A measure of the total exposure to a drug over time, used to assess bioavailability and bioequivalence.
  • Maximum plasma concentration (Cmax): The highest concentration of a drug in the blood plasma after administration.
  • Crossover study: A type of clinical trial where participants receive different treatments in a specific sequence, allowing comparison of effects within the same individual.

References

  1. https://clinicaltrials.gov/study/NCT04389567
  2. https://clinicaltrials.gov/study/NCT01910090
  3. https://clinicaltrials.gov/study/NCT01511731
  4. https://clinicaltrials.gov/study/NCT00945750
  5. https://clinicaltrials.gov/study/NCT04504240
  6. https://clinicaltrials.gov/study/NCT01937078
  7. https://clinicaltrials.gov/study/NCT05866627
  8. https://clinicaltrials.gov/study/NCT05122208